MedTrace Logo

Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest

NCT06744361 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 282

Last updated 2024-12-20

No results posted yet for this study

Summary

OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI). Despite advances in resuscitation techniques, the neurological outcomes for survivors remain poor. Current post-resuscitation practices lack specific neuroprotective strategies. Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, has shown potential neuroprotective properties in preclinical and clinical studies due to its ability to inhibit excitotoxicity and reduce neuronal apoptosis. This trial hypothesizes that ketamine, when used for sedation in OHCA patients, may offer superior neuroprotective benefits compared to the commonly used sedative propofol. By comparing the effects of ketamine and propofol on neuronal damage markers and long-term neurological outcomes, this study aims to identify a potentially effective intervention to improve the prognosis of OHCA patients.

Conditions

  • Out-of-hospital Cardiac Arrest (OHCA)

Interventions

DRUG

esketamine hydrochloride

Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine

DRUG

propofol

Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol

Sponsors & Collaborators

  • Christian Hassager

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2027-09-01
Completion
2027-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06744361 on ClinicalTrials.gov